Myocardial reperfusion injury. Platelet-activating factor stimulates polymorphonuclear leukocyte hydrogen peroxide production during myocardial reperfusion.
暂无分享,去创建一个
S. Calvano | A. Hawes | O. Isom | J. Zelano | A. Antonacci | W. Ko | K. Krieger | W. D. Lazenby | Y. Shin | W. Lazenby | A. S. Hawes
[1] S. Moore,et al. Roles of the neutrophil and other mediators in adult respiratory distress syndrome. , 1989, Mayo Clinic proceedings.
[2] B. Seed,et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. , 1989, Science.
[3] R. Kloner,et al. “Reperfusion Injury” by Oxygen‐Derived Free Radicals?: Effect of Superoxide Dismutase Plus Catalase, Given at the Time of Reperfusion, on Myocardial Infarct Size, Contractile Function, Coronary Microvasculature, and Regional Myocardial Blood Flow , 1989, Circulation research.
[4] P. J. Simpson,et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. , 1988, The Journal of clinical investigation.
[5] G. Lobley,et al. Changes in protein turnover in hypertrophying plantaris muscles of rats: effect of fenbufen--an inhibitor of prostaglandin synthesis. , 1987, Prostaglandins.
[6] P. Braquet,et al. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes. , 1987, Biochemical and biophysical research communications.
[7] M. Weisfeldt,et al. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. , 1987, Circulation.
[8] F. Snyder,et al. Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig. , 1987, Prostaglandins.
[9] P. Chatelain,et al. Neutrophil accumulation in experimental myocardial infarcts: relation with extent of injury and effect of reperfusion. , 1987, Circulation.
[10] M. Weisfeldt,et al. Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. , 1986, Circulation.
[11] W. Nayler,et al. Reperfusion injury: laboratory artifact or clinical dilemma? , 1986, Circulation.
[12] P. Menasché,et al. A comparative study of free radical scavengers in cardioplegic solutions. Improved protection with peroxidase. , 1986, The Journal of thoracic and cardiovascular surgery.
[13] S. Kunkel,et al. Protective effects of N-2-mercaptopropionyl glycine against myocardial reperfusion injury after neutrophil depletion in the dog: evidence for the role of intracellular-derived free radicals. , 1986, Circulation.
[14] S. Lemeshow,et al. Cardiac performance during reperfusion improved by pretreatment with oxygen free-radical scavengers. , 1986, The Journal of thoracic and cardiovascular surgery.
[15] L. Greenfield,et al. Prevention of free radical-induced myocardial reperfusion injury with allopurinol. , 1985, The Journal of thoracic and cardiovascular surgery.
[16] B. Lucchesi,et al. Canine Myocardial Reperfusion Injury: Its Reduction by the Combined Administration of Superoxide Dismutase and Catalase , 1984, Circulation research.
[17] L. Greenfield,et al. Inhibition of surgically induced ischemia/reperfusion injury by oxygen free radical scavengers. , 1983, The Journal of thoracic and cardiovascular surgery.
[18] M. Schork,et al. Reduction of the Extent of Ischemic Myocardial Injury by Neutrophil Depletion in the Dog , 1983, Circulation.
[19] M. Seeds,et al. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. , 1983, Journal of immunology.
[20] M. Kirsh,et al. Superoxide dismutase plus catalase enhances the efficacy of hypothermic cardioplegia to protect the globally ischemic, reperfused heart. , 1982, The Journal of thoracic and cardiovascular surgery.
[21] L. McManus,et al. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). , 1981, Journal of immunology.
[22] J. O'flaherty,et al. Selective desensitization of neutrophils: further studies with 1-O-alkyl-sn-glycero-3-phosphocholine analogues. , 1981, Journal of immunology.
[23] J. O'flaherty,et al. 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. , 1981, The American journal of pathology.
[24] R. Gunnar,et al. Chemotactic activity in the coronary sinus after experimental myocardial infarction: effects of pharmacologic interventions on ischemic injury. , 1977, The American journal of cardiology.
[25] Jennings Rb,et al. EXPERIMENTAL ACUTE MYOCARDIAL INFARCTION; HISTOLOGIC AND HISTOCHEMICAL STUDIES OF EARLY MYOCARDIAL INFARCTS INDUCED BY TEMPORARY OR PERMANENT OCCLUSION OF A CORONARY ARTERY. , 1964 .
[26] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[27] I. Fridovich. The Biology of Oxygen Radicals: Threats and Defenses , 1988 .
[28] M. Weisfeldt,et al. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. , 1987, Circulation.
[29] D. Hanahan. Platelet activating factor: a biologically active phosphoglyceride. , 1986, Annual review of biochemistry.